Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus

Log in or subscribe to view full content.
Article is also available for purchase the article in one of the available formats.
Anthony H. Barnett, MD

Table of Contents

Postgraduate Medicine:

Volume 125 No. 5


Clinical Features

Purchase this article in one of the formats specified below:

DOI: 10.3810/pgm.2013.09.2698
Abstract: Most patients with type 2 diabetes mellitus (T2DM) are overweight or obese. Both T2DM and overweight/obesity are associated with increased patient risk of cardiovascular events and mortality. Despite being the recognized cornerstone of treatment, weight loss and maintenance of weight loss are difficult for patients with T2DM, particularly as treatments for T2DM may cause weight gain. Sodium glucose cotransporter 2 (SGLT2) inhibitors, a new class of drug for the treatment of patients with T2DM, reduce renal glucose reabsorption, resulting in urinary glucose excretion. Due to the caloric loss associated with decreased glucose in urine, treatment with SGLT2 agents offers the benefit of weight loss to patients, as well as reduction in hyperglycemia. Clinical trials of SGLT2 inhibitors in patients with T2DM, ranging in length from 4 to 90 weeks, have shown patient weight reductions from baseline of up to 4.7 kg. Such weight loss may have beneficial effects on adherence to medication, glycemic control, and cardiovascular risk in patients with T2DM.

Keywords: antidiabetes drugs; obesity; overweight; sodium glucose cotransporter 2 (SGLT2) inhibitors; type 2 diabetes mellitus